Prostate%20cancer Signs and Symptoms

Signs and Symptoms

Introduction

Second most common cancer in men; one of the most common cancers in men >50 years of age

Signs and Symptoms

Weak urinary stream, incomplete bladder emptying
Polyuria, nocturia
Hematuria
Erectile dysfunction
Pelvic pain, back pain, chest pain
Lower extremity weakness or numbness
Loss of bladder or bowel control

Risk Factors

Age (increased risk in men >50 years old)
Positive family history: 1st- or 2nd-degree relatives diagnosed with metastatic prostate, ovarian, breast (female ≤45 years old), colorectal, endometrial (≤50 years old) or pancreatic cancer, and those with ≥2 1st- or 2nd-degree relatives diagnosed with prostate, breast, colorectal or endometrial cancer at any age
Ethnicity (African ancestry, Ashkenazi Jewish descent)
Chemical exposures (toxic combustion products)
Genetic mutations: Breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2), ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHEK2), homeobox B13 (HOXB13), epithelial cellular adhesion molecule (EPCAM), nibrin (NBN), tumor protein 53 (TP53), partner and localizer of BRCA2 (PALB2), deoxyribonucleicacid (DNA) mismatch repair genes [mutS homolog 2 (MSH2), mutL homolog 1 (MLH1), Lynch syndrome, mutS homolog 6 (MSH6), post-meiotic segregation increased 2 (PMS2)], insulin-like growth factor-1 (IGF-1)
Other risk factors under research include a positive medical history of inflammation of the prostate gland [eg prostatitis, sexually transmitted diseases (STDs), proliferative inflammatory atrophy (PIA)] and vasectomy

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Intensive care unit (ICU) patients are at risk of developing serious infections with multidrug-resistant organisms (MDROs), which require appropriate and adequate antibiotic coverage. Early empirical coverage is pivotal in saving patients’ lives. At a recent webinar co-organized by the Society of Infectious Disease (Singapore) and Pfizer, renowned Professor David Paterson, Professor of Medicine and Director, The University of Queensland Centre for Clinical Research, and Consultant Infectious Diseases Physician, Royal Brisbane and Women’s Hospital, Brisbane, Australia, discussed the role of newer antimicrobial agents, including ceftazidime-avibactam (Zavicefta) in the management of MDROs in the ICU. Dr Wong Sin Yew, Infectious Disease Physician at Gleneagles Medical Centre and Mount Elizabeth Novena Specialist Centre, Singapore, chaired the event.

Improving survival outcomes with systemic therapy in advanced hepatocellular carcinoma

02 Apr 2021

At the 3rd Bayer Hepatocellular Carcinoma (HCC) Masterclass, three distinguished speakers shared their insights into the management of intermediate and advanced HCC in Malaysia. Topics discussed include current treatment landscape and updates in disease management, as well as two case studies that highlighted the role of tyrosine kinase inhibitors (TKIs) in improving the overall survival (OS) of patients with advanced HCC.

New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations

31 Mar 2021

At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT^®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.